S&P 500 Consumer Staples Sector SEC Filings — March 09, 2026

09-03-2026

Signet Jewelers announced preliminary Q4 FY26 sales of $2.34-2.35B with SSS declining 0.7-0.9% YoY despite AUR up 4-5% and sequential monthly improvements, while full year FY26 sales reached ~$6.8B with SSS up 1.2-1.3% YoY and AUR up 6-7%. Operating income is projected at $313-318M for Q4 (adjusted $322-327M) and $388-393M for FY26 (adjusted $510-515M), with expected free cash flow exceeding $500M amid a modest gross merchandise margin decline from broader promotions. Sales momentum continued positively into Valentine's Day and March, supported by the Grow Brand Love strategy across Kay, Zales, and Jared.

• ·Asset impairments: $7M in Q4 FY26, $91M in FY26 (primarily goodwill and indefinite-lived intangible assets).
• ·Restructuring and related charges: $27M in FY26 (Grow Brand Love strategy).
• ·Loss on divestitures: $2M in Q4 FY26, $4M in FY26 (UK prestige watch business).
• ·Operates ~2,600 stores.
• ·Investor conferences: Citi March 9, BofA March 10, UBS March 11, 2026; presentation webcast March 9 at 4:15 PM ET.
• ·FY27 guidance and strategic priorities to be provided March 16, 2026 (next Thursday).

09-03-2026

Universal Logistics Holdings, Inc. announced on March 3, 2026, that its condensed consolidated financial statements for the quarter ended September 27, 2025, should no longer be relied upon due to an error in the goodwill impairment analysis for its intermodal reporting unit, requiring a $43.2 million additional goodwill impairment charge that fully impairs the unit's goodwill. The error stemmed from including $46.7 million of inappropriate deferred tax liabilities in the carrying value. While the correction does not affect revenues, operating cash flows, liquidity, or debt covenant compliance, the company plans to file an amended 10-Q and has noted it in the context of a previously disclosed material weakness in internal controls.

• ·Error identified during Q4 2025 goodwill impairment review procedures.
• ·Company intends to file Amendment No. 1 to Form 10-Q for quarter ended September 27, 2025, as soon as practicable.
• ·Discussed with Audit Committee and independent auditors Grant Thornton LLP.
• ·Relates to previously disclosed material weakness in internal control over financial reporting.

09-03-2026

09-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed a Form 8-K on March 9, 2026, under Items 8.01 and 9.01, announcing the issuance of a press release titled 'The Top 20 Things You Probably Did Not Know About AITX and RAD', attached as Exhibit 99.1. The information is furnished and explicitly stated as not material or filed for liability purposes under the Exchange Act.

09-03-2026

Mobile-health Network Solutions (MNDR), a Cayman Islands-incorporated foreign private issuer operating telemedicine and medical services in Southeast Asia (Singapore, Vietnam, Malaysia, Indonesia), filed a preliminary F-1 registration statement on March 9, 2026, for a proposed IPO. As an emerging growth company, it is exempt from certain stringent executive compensation and other disclosure rules applicable to U.S. domestic issuers. The filing references financial periods ending June 30, 2025, and prior years, along with subsidiaries and intangible assets like the MaNaDr App software, but no specific financial metrics are disclosed in the provided excerpt.

• ·Subsidiaries acquired on specific dates: KlinikKWongSdnBhd (Jul 3, 2024), PTMobileHealthNetworkSolution (Aug 6, 2024), SkylinkInnovationsPteLtd (Nov 27, 2024), MedilinkClinicPteLtd (Jan 13, 2025).
• ·Intangible assets include Patents, MaNaDr App Software, Trademarks, and Software Under Development as of Jun 30, 2025.
• ·Operations in SG, VN, MY, ID for FY ended Jun 30, 2025.

09-03-2026

Future Money Acquisition Corporation, a Cayman Islands-incorporated blank check company (SIC 6770), filed Amendment No. 2 to its Form S-1 registration statement (No. 333-291996) on March 6, 2026, as an exhibits-only update with no changes to the main prospectus. New exhibits include specimen unit/share certificates, legal opinions, auditor consents, and a filing fee table, while previously filed exhibits remain unchanged. The filing advances the proposed IPO, with sales to commence as soon as practicable post-effectiveness.

• ·Principal executive offices: 475 Brannan St, San Francisco, CA 94107; Phone: +1 6479860980
• ·Agent for service: Cogency Global Inc., 122 East 42nd Street, 18th Floor, New York, NY 10168
• ·Key exhibit dates: Securities Subscription Agreement (Nov 24, 2025); Promissory Note (Oct 2, 2025, as amended)
• ·Registrant status: Non-accelerated filer, smaller reporting company, emerging growth company
• ·Newly filed exhibits (**): 1.1 (Underwriting Agreement), 4.1 (Unit Cert.), 4.2 (Share Cert.), 5.1 (Harney Opinion), 23.1 (HYYH Consent)

09-03-2026

Melar Acquisition Corp. I/Cayman, a blank check company with no operating history or revenues, filed its 10-K on March 9, 2026, for the year ended December 31, 2025, disclosing risks related to completing an initial Business Combination, including the proposed Everli Business Combination which could result in substantially all assets and revenue in a foreign country. The filing details potential Working Capital Loans up to $1.5M from the Sponsor or affiliates, convertible into warrants, and lists beneficial owners via Schedule 13G filings from entities like LMR Partners, AQR, Wolverine (holding 926,328 Public Shares as of Sep 30, 2025), Mizuho, and others. No operating performance metrics are provided, consistent with SPAC status.

• ·Company inception: March 11, 2024
• ·Financial statements compare year ended December 31, 2025 to period from inception through December 31, 2024
• ·Risk of negative interest rates on Trust Account investments potentially reducing per-share redemption value
• ·Schedule 13G filing dates: November 14, 2024 (LMR, AQR); August 14, 2025 (Meteora); October 10, 2025 (Wolverine); November 13, 2025 (Mizuho); February 11, 2026 (W.R. Berkley); March 21, 2025 (Barclays)

09-03-2026

Israel Acquisitions Corp, a SPAC, entered into a waiver of its Administrative Services Agreement with sponsor Israel Acquisitions Sponsor LLC, waiving all $10,000 monthly fees until business combination or liquidation and $240,000 in accrued fees as of December 31, 2025. The company also executed a second amendment to its January 26, 2025 Business Combination Agreement with Gadfin Ltd. and Gadfin Regev Holdings Ltd., extending the termination date to March 16, 2026 while removing prior automatic extension provisions. This 8-K/A filed on March 9, 2026, amends a prior filing to disclose the second BCA amendment.

• ·Original Administrative Services Agreement dated January 12, 2023
• ·Original Business Combination Agreement dated January 26, 2025; first amendment dated July 2, 2025
• ·Waiver and Second BCA Amendment both dated December 31, 2025

09-03-2026

Relmada Therapeutics announced positive 12-month Phase 2 interim data for NDV-01 in high-risk NMIBC, achieving a 76% complete response (CR) rate at 12 months (95% at any time) and 80% CR at 12 months (94% anytime) in BCG-unresponsive patients, with no progression to muscle-invasive disease, no radical cystectomies, and a favorable safety profile (no ≥Grade 3 TRAEs or discontinuations). The results support advancing to the Phase 3 RESCUE registrational program in mid-2026 for 2L BCG-unresponsive and adjuvant intermediate-risk NMIBC. While CR rates showed slight declines over time (87% at 3 months to 76% at 12 months overall), no major negative outcomes were reported.

• ·No patients progressed to muscle-invasive disease or underwent radical cystectomy.
• ·Phase 3 RESCUE Pathway 1: Open-label RCT in adjuvant intermediate-risk NMIBC post-TURBT vs observation (primary endpoint: DFS).
• ·Phase 3 RESCUE Pathway 2: Single-arm trial in 2L BCG-unresponsive NMIBC with CIS (primary endpoint: CR rate at any time).
• ·Upcoming milestones: US IND clearance mid-2026, Phase 3 initiation mid-2026, initial 3-month Phase 3 results YE 2026.
• ·NDV-01 patents protected through 2038; administration <5 minutes without anesthesia.

09-03-2026

Korn Ferry reported Q3 FY'26 fee revenue of $717.4 million, up 7% YoY (4% constant currency), driven by growth across all solutions including Executive Search (+13%), Consulting (+5%), Professional Search & Interim (+5%), Digital (+4%), and RPO (+3%). Net income attributable to Korn Ferry increased 12% YoY to $65.3 million (9.1% margin), adjusted EBITDA rose 8% to $123.1 million (17.2% margin), and estimated remaining fees reached $1.85 billion (+11% YoY). However, adjusted EBITDA margins were largely flat YoY across most solutions, Consulting hours worked declined 8% to 317 thousand, consultant headcounts decreased in Consulting (-7%) and Digital (-10%), and RPO new business fell sharply to $54.4 million from $209.9 million.

• ·Q4 FY'26 outlook: fee revenue $730M-$750M; diluted EPS $1.34-$1.40.
• ·YTD FY'26 fee revenue $2,147.7M (+6% YoY).
• ·Professional Search & Interim: Permanent Placement engagements billed 1,715 (flat YoY); Interim remaining fees $106.6M (-4% YoY).

09-03-2026

Amex GBT reported strong Q4 FY2025 revenue of $792M (+34% YoY) and full-year revenue of $2.718B (+12% YoY), driven by the CWT acquisition, with Adjusted EBITDA of $130M (+17%) and $532M (+11%) respectively; however, gross margins declined 243bps to 55% in Q4 and 15bps to 57% FY, Adjusted EBITDA margins fell 233bps to 16% in Q4 while flat at 20% FY, and free cash flow dropped sharply to $13M (-66%) in Q4 and $104M (-37%) FY. The company reiterated FY2026 guidance for 19-21% revenue growth to $3.235B-$3.295B and Adjusted EBITDA of $615M-$645M (+16-21%), doubled share buyback authorization to $600M, and highlighted 96% customer retention and $3.3B in Total New Wins Value.

• ·Q4 TTV growth of 45% and Transaction Growth of 37%, FY TTV 17% and Transaction Growth 14%, primarily due to CWT acquisition, business travel demand, and share gains.
• ·Excluding CWT, Q4 revenue growth was 8%.
• ·Net Debt / LTM Adjusted EBITDA improved slightly to 1.9x from 1.8x.
• ·CWT acquisition closed in September 2025.
• ·Next-gen Egencia launching in April 2026 with AI features.

09-03-2026

Korro Bio, Inc. (KRRO) announced an oversubscribed $85M PIPE financing led by Venrock Healthcare Capital Partners with participation from new and existing investors, expected to close on or about March 10, 2026. Gross proceeds, combined with $85.2M in unaudited cash, cash equivalents, and marketable securities as of December 31, 2025, are expected to extend the cash runway into the second half of 2028 to fund clinical milestones for KRRO-121 in urea cycle disorders and the GalNAc-conjugated AATD program. The financing involves selling 4,501,928 common shares at $11.11 each and pre-funded warrants for 3,148,836 shares.

• ·PIPE closing subject to customary conditions on or about March 10, 2026
• ·Placement agents: Citigroup, Cantor, Oppenheimer & Co., William Blair
• ·Company to file SEC registration for resale of PIPE shares and warrant shares
• ·Cash runway extends into second half of 2028

09-03-2026

Castellum, Inc. (CTM) reported FY2025 revenues of $52.9M, up 18.1% YoY from $44.8M in 2024, driven by gross profit growth of 6.0% to $19.4M, while total operating expenses fell 13.0% to $22.2M, narrowing net loss to common shareholders to $2.5M (-75.2% improvement). However, cash flow from operating activities deteriorated to $(1.9M) from $1.1M in 2024, and FY2024 revenues had declined 1.1% YoY from $45.2M in 2023 amid flat gross profit performance (-2.2%). Balance sheet strengthened with total assets at $41.9M (up from $37.8M) and liabilities reduced to $6.2M from $17.7M.

• ·Common shares used in net loss per share calculation: 92,962,823 (FY2025 basic and diluted)
• ·Net cash from financing activities: $4.7M (FY2025)
• ·Derivative liability reduced to $262K from $883K (Dec 31, 2025 vs 2024)
• ·Revolving credit facility fully repaid ($0 from $2.0M)
• ·Investment in joint ventures/captive insurance: $100K (FY2025)

09-03-2026

Kronos Worldwide, Inc. reported a Q4 2025 net loss of $82.8 million ($0.72 per share), widening from a $13.2 million loss ($0.12 per share) in Q4 2024, driven by higher unabsorbed fixed production costs from curtailments and lower TiO2 prices, despite higher sales volumes. Full-year 2025 net loss was $110.9 million ($0.96 per share) versus 2024 net income of $86.2 million ($0.75 per share), with net sales down 1% YoY to $1.9B due to 4% lower average TiO2 prices partially offset by higher volumes, while production volumes declined 10% YoY amid 77% capacity utilization versus 96% in 2024. TiO2 segment swung to a Q4 loss of $59.4 million from $33.1 million profit and FY loss of $22.2 million from $141.0 million profit.

• ·Effective July 16, 2024, acquired 50% JV interest in LPC, making it wholly-owned; FY 2024 net income included $64.5M non-cash gain on remeasurement.
• ·Q4 2025 cost of sales included $54M unabsorbed fixed costs; FY 2025 EBITDA included $4.6M non-cash gain on LPC earn-out reduction.
• ·Currency fluctuations (primarily euro) increased net sales by $13M in Q4 2025 and $24M in FY 2025 YoY.
• ·Production capacity: Q1-Q4 2025 at 93%, 81%, 80%, 55%; Q1-Q4 2024 at 87%, 99%, 92%, 97%.

09-03-2026

MYOMO, Inc. reported total revenue of $40.9M for FY 2025, up 26% YoY from $32.6M, driven by growth in direct billing (+20%), international (+48%), and U.S. O&P (+100%), though VA revenue declined to $0.8M from $1.2M. Gross profit rose 16% to $26.9M but gross margin contracted 5.5 percentage points to 65.7% due to 50% higher cost of revenue; operating expenses surged 40% to $41.3M, resulting in a widened GAAP net loss of $15.6M from $6.2M and Adjusted EBITDA loss of $11.5M from $5.1M. Cash and equivalents fell to $14.1M from $24.4M amid $14.5M operating cash burn.

• ·R&D expenses increased 46% YoY to $6.9M.
• ·G&A expenses rose 13% YoY to $14.0M.
• ·Net cash used in operating activities worsened to $14.5M from $3.3M.
• ·Short-term investments grew to $4.3M from $0.5M.
• ·Working capital declined to $19.2M from $22.6M.

09-03-2026

Ellington Credit Company's Board of Trustees declared a monthly common dividend of $0.08 per share on March 9, 2026, payable on April 30, 2026 to common shareholders of record as of March 31, 2026. The announcement was issued via press release filed as Exhibit 99.1.

• ·Trading symbol: EARN on The New York Stock Exchange
• ·Registrant incorporated in Delaware, Commission File Number 811-24071, IRS EIN 46-0687599

09-03-2026

On March 6, 2026, Mathew Tirman, President of Satellogic Inc., notified the company of his voluntary resignation effective March 31, 2026, to pursue other opportunities, with no severance benefits provided. The company has no immediate plans to fill the role and intends to distribute his duties among other executives. This departure occurs amid the company's status as an emerging growth company with Class A Common Stock (SATL) and Warrants (SATLW) listed on Nasdaq Capital Market.

• ·Company address: 210 Delburg Street, Davidson, NC 28036
• ·Telephone: (704) 802-2041
• ·Satellogic Inc. is an emerging growth company
• ·Securities: Class A Common Stock (SATL) and Warrants (SATLW) on Nasdaq Capital Market

09-03-2026

Envirotech Vehicles, Inc. entered into a Securities Purchase Agreement dated March 6, 2026, to issue and sell debentures with an aggregate principal amount of up to $11M ($4M at First Closing and $7M at Second Closing) at a purchase price equal to 96% of the principal amount, along with warrants exercisable into 1,291,778 common shares as a commitment fee. The Second Closing is contingent on the effectiveness of the SEPA Registration Statement and must occur by June 30, 2026. Issuances are subject to a Nasdaq Exchange Cap of 2,584,850 common shares (19.99% of outstanding shares) without shareholder approval.

• ·First Closing to occur on first Business Day conditions are met, at 10:00 a.m. New York time
• ·Second Closing on first Business Day after SEPA Registration Statement declared effective by SEC
• ·Buyer is accredited investor acquiring Securities for investment purposes, not public distribution
• ·Securities include restrictive legends unless registered or Rule 144 applicable

09-03-2026

Barnwell Industries, Inc. issued a press release on March 4, 2026, incorporated into its 8-K filing, highlighting key operational results from its recently filed Form 10-Q for the first quarter of fiscal year 2026. The release emphasizes the continued performance and reliability of the Company's Canadian oil production during the winter operating season. No specific financial metrics or period-over-period comparisons were detailed in the filing.

• ·Filing dated March 9, 2026
• ·Event date: March 4, 2026
• ·Principal offices: 24 Greenway Plaza, Suite 1800Q, Houston, Texas 77046

09-03-2026

Kontoor Brands, Inc. (KTB) issued a notice for its 2026 Annual Shareholder Meeting to be held virtually on April 23, 2026, at 11:00 AM ET. Proposals include electing six director nominees (Scott H. Baxter, Maryelizabeth R. Campbell, Ashley D. Goldsmith, Mark L. Schiller, Robert K. Shearer, Shelley Stewart, Jr.), ratifying PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending January 2, 2027, approving named executive officer compensation, and an advisory vote on say-on-pay frequency (board recommends 1 year). The board recommends voting FOR all main proposals; no financial performance metrics or changes are disclosed.

• ·Vote deadline: April 22, 2026, 11:59 PM ET
• ·Materials request deadline: April 9, 2026
• ·Meeting URL: www.virtualshareholdermeeting.com/KTB2026

09-03-2026

Stellar V Capital Corp., a SPAC, reported net income of $5.3M for the year ended December 31, 2025, driven by $5.7M in interest earned on marketable securities held in its Trust Account which grew to $156.7M, compared to a net loss of $0.16M in the stub period from inception (July 12, 2024) through December 31, 2024. However, loss from operations widened to $0.59M from $0.08M due to higher general and administrative costs of $0.59M versus $0.08M. Total assets expanded to $157.2M from $0.36M, while shareholders' deficit increased to $4.9M from $0.05M.

• ·Sponsor received 6,059,925 Class B founder shares for $25,000 consideration.
• ·Redemption price anticipated at approximately $10.07 per share, actual $10.45 as of Dec 31, 2025.
• ·Up to $1.5M working capital loans from sponsor convertible into private units at $10.00 per unit.
• ·Founder shares subject to lock-up until 6 months post-business combination or price/liquidation triggers.

09-03-2026

ARKO Petroleum Corp. issued and sold 1,459,112 shares of Class A common stock to underwriters UBS Securities LLC and Raymond James & Associates, Inc. on March 9, 2026, following their exercise of the over-allotment option on March 5, 2026. The company received net proceeds of $24.4 million after underwriters’ discounts and commissions from the IPO-related option, which allowed up to 1,666,666 additional shares.

• ·Over-allotment option period: 30 days following IPO closing
• ·Registrant address: 8565 Magellan Pkwy, Suite 400, Richmond, Virginia 23227-1150

09-03-2026

On March 6, 2026, the board of directors of the general partner of Kimbell Royalty Partners, LP approved a common unit repurchase program authorizing up to $100M in repurchases through December 31, 2027. The program will be executed opportunistically using cash on hand, free cash flow from operations, or permitted borrowings, with purchases in open market transactions compliant with Rule 10b-18 or private negotiations. The Board may suspend, modify, extend, or discontinue the program at any time based on market conditions and other factors.

• ·Registrant's address: 777 Taylor Street, Suite 810, Fort Worth, Texas 76102
• ·Telephone: (817) 945-9700

09-03-2026

BriaCell Therapeutics Corp. held its Annual General and Special Meeting on March 5, 2026, with 3,502,695 common shares represented (48% quorum out of 7,250,487 outstanding). Shareholders ratified MNP LLP as auditors (3,431,761 For vs. 70,934 Withhold), elected six directors including Dr. William V. Williams and Dr. Jane Gross (each with ~1.8M For votes vs. ~40-50k Withhold and 1,615,665 broker non-votes), and re-approved the Omnibus Equity Incentive Plan (1,524,081 For vs. 362,949 Against and 1,615,665 broker non-votes). All proposals passed with majority support despite notable broker non-votes and some opposition.

• ·Director election votes: Dr. Jane Gross (1,837,220 For, 49,810 Withhold); Mr. Jamieson Bondarenko (1,847,842 For, 39,188 Withhold); Dr. William V. Williams (1,837,675 For, 49,355 Withhold); Dr. Rebecca Taub (1,837,729 For, 49,301 Withhold); Mr. Vaughn C. Embro-Pantalony (1,847,644 For, 39,386 Withhold); Mr. Martin Schmieg (1,844,132 For, 42,898 Withhold)
• ·Record date: January 26, 2026
• ·Proxy statement filed: February 12, 2026

09-03-2026

Wellgistics Health, Inc. (WGRX) filed an 8-K on March 9, 2026, under Items 7.01 and 9.01, disclosing a press release (Exhibit 99.1) pursuant to Regulation FD. The filing includes standard disclaimers that the information is furnished, not filed, and contains forward-looking statements with risks detailed in prior SEC filings, including the Form S-1 effective September 25, 2025. No specific financial metrics, performance data, or period comparisons are provided in the filing.

• ·Commission File Number: 001-42530
• ·IRS Employer Identification No.: 93-3264234
• ·Form S-1 declared effective by SEC on September 25, 2025
• ·Principal executive offices: 3000 Bayport Drive Suite 950, Tampa, FL 33607
• ·Telephone: (844) 203-6092
• ·Common Stock: $0.0001 par value per share, trading symbol WGRX

09-03-2026

Alternus Clean Energy, Inc. and its wholly owned subsidiary Alt Alliance LLC entered into a Subscription Agreement with an unnamed investor for a Promissory Note and shares of Series C Convertible Preferred Stock in an unspecified Principal Amount. The agreement includes standard representations, warranties, and conditions for an accredited or non-U.S. investor, with payment via wire transfers in initial and subsequent tranches per a drawdown schedule. No specific financial amounts, performance metrics, or period-over-period changes are disclosed in the filing.

• ·Investor must wire initial tranche upon acceptance, with subsequent tranches per Schedule 1 drawdown schedule.
• ·Securities issued in reliance on Regulation D or Regulation S exemptions; resale restrictions apply for 12 months for non-U.S. persons.
• ·Governing law: Nevada; disputes resolved by arbitration in New York under ICC Rules.

09-03-2026

Pelican Acquisition Corp disclosed under Regulation FD a social media post by incoming Greenland Energy Company director Larry G. Swets, Jr. republishing a Newsmax appearance by Robert Price, and an Oilprice.com article highlighting the potential of Greenland’s Jameson Land basin as the next big oil discovery in connection with the pending Business Combination involving Pelican, Greenland Exploration Limited, March GL, and PubCo (Greenland Energy Company). The Form S-4 registration statement, including the proxy statement/prospectus, was declared effective on February 17, 2026, with materials available on SEC.gov. While the disclosures promote exploratory potential, the filing emphasizes extensive risks including merger delays, shareholder redemptions, regulatory hurdles, and operational uncertainties that could prevent completion.

• ·Social media post furnished as Exhibit 99.1
• ·Oilprice.com article furnished as Exhibit 99.2 and accessible at https://oilprice.com/Energy/Crude-Oil/Greenlands-Untested-Oil-Basin-Could-Be-the-Next-Big-Discovery.html
• ·Pelican 10-Qs filed for quarters ended July 31, 2025 (Sep 15, 2025) and April 30, 2025 (Jun 27, 2025); S-1 effective May 22, 2025

09-03-2026

On March 3, 2026, the Board of Directors of Elutia Inc. adopted the Elutia Inc. 2026 Inducement Award Plan to attract and retain new employees through equity incentives, authorizing a maximum of 2,000,000 shares of Class A common stock. The plan permits grants of stock options, restricted stock units, and other awards exclusively to individuals not previously employed by the company (or after a bona fide interruption), with no stockholder approval required. The Compensation Committee administers the plan, with standard provisions for exercise prices at 100% of fair market value and terms up to 10 years.

• ·Awards are non-transferable and subject to the company's clawback policies.
• ·In a change of control, awards may be assumed, substituted, or terminated for cash/property unless otherwise elected.
• ·No incentive stock options may be granted under the plan.

09-03-2026

Belpointe PREP, LLC, through its indirect wholly-owned subsidiary BPOZ 100 Tokeneke Holding, LLC, extended a $5M convertible promissory note at 3.6% interest to 100 Tokeneke Road, LLC to fund the purchase of real property at 100 Tokeneke Road, Darien, Connecticut. Concurrently, Belpointe Tokeneke Investment, LLC—a related party linked to family members of CEO Brandon E. Lacoff—provided a $3.25M convertible note, with $625K mandatorily converted into a 50% ownership stake in 100 Tokeneke Partners, LLC. Both transactions were approved by the Company's Conflicts Committee in compliance with related party policies.

• ·Loans bear interest at 3.6% per annum (365/366-day year basis) and are due March 3, 2026 unless converted.
• ·Convertible into Class A units of Tokeneke Partners at $14.50 per unit (subject to adjustment).
• ·Notes to be filed as exhibits in Q1 2026 10-Q.

09-03-2026

On March 9, 2026, Ellington Financial Inc. announced quarterly and monthly dividend declarations via press release: $0.13 per share for common stock (monthly), $0.390625 per share for 6.250% Series B Preferred Stock (quarterly), $0.5390625 per share for 8.625% Series C Preferred Stock (quarterly), and $0.4375 per share for 7.00% Series D Preferred Stock (quarterly). These dividends reflect stable payout commitments to shareholders across share classes with no changes or reductions indicated.

• ·Common stock dividend payable April 30, 2026 to record date March 31, 2026.
• ·Series B and Series C preferred dividends payable April 30, 2026 to record date March 31, 2026.
• ·Series D preferred dividend payable March 30, 2026 to record date March 20, 2026.

09-03-2026

Clearway Energy, Inc.'s Board of Directors approved a proposal to amend and restate the certificate of incorporation, converting each share of Class A common stock (CWEN.A) into one share of Class C common stock (CWEN), with the conversion to occur automatically at 12:01 a.m. ET on the second business day after filing if approved. The proposal will be submitted to stockholders at the 2026 Annual Meeting in Q2 2026, requiring 66 2/3% of combined voting power and a majority of Class A voting power for approval. The company highlighted risks including failure to obtain approvals, litigation, market impacts, and execution challenges.

• ·Record date for voting eligibility: close of business on March 19, 2026
• ·Definitive proxy statement on Schedule 14A to be filed with SEC
• ·Prior filings referenced: 2025 Proxy Statement (filed March 13, 2025), 10-K for year ended December 31, 2025 (filed February 24, 2026)

09-03-2026

OPAL Fuels LLC entered a subscription agreement dated March 6, 2026, with Preferred Fuels LLC to purchase up to 1,800,000 Series A Preferred Units at $100 per unit for a committed $180M, including an initial $120M investment, with the balance drawable within one year. The agreement provides a right of first offer for an additional $70M and includes fees up to $3.75M transaction fees, 1% annual undrawn commitment fees, and $1.7M expense reimbursement. Proceeds will primarily redeem preferred securities held by Mendocino Capital, LLC, with remaining funds for general corporate purposes, working capital, and capex.

• ·Execution Date: March 6, 2026
• ·Availability Period: 1 year from Initial Closing
• ·ROFO Sunset Date: 2 years from Execution Date
• ·Closings in minimum tranches of $10M, up to 2 years from Initial Closing
• ·Use of proceeds includes project-level financing for projects in Schedule B

09-03-2026

Technology & Telecommunication Acquisition Corp (TETUF) reported a net loss of $731k for FY ended Nov 30, 2025, compared to net income of $617k in FY 2024, driven by higher formation costs ($1.13M vs $1.06M) and lower interest income from trust ($400k vs $1.68M). Balance sheet shows drastic declines with total assets at $170k (down 99.5% YoY) and trust account at $142k (down 99.6% YoY) due to $32M in share redemptions, while shareholders' deficit worsened to $(10.5M) from $(9.3M). Cash balance fell sharply to $340 from $25k amid ongoing SPAC operations without a completed business combination.

• ·Weighted average Class A ordinary shares: 4,098,270 (FY2025) vs 6,194,483 (FY2024), decline due to redemptions.
• ·Basic and diluted EPS: $(0.18) (FY2025) vs $0.10 (FY2024).
• ·Accounts payable and accrued liabilities: $2.31M (2025) vs $1.55M (2024), up 49%.
• ·Extension loan: $2.82M (2025) vs $2.77M (2024).
• ·Working capital loan: $1.36M (2025) vs $1.05M (2024).
• ·Deferred Underwriter Commission unchanged at $4.03M.
• ·Net cash used in operating activities improved to $342k (2025) from $732k (2024).

09-03-2026

Dennis J. Wilson and related Reporting Persons filed Amendment No. 14 to Schedule 13D on March 9, 2026, reporting no change in beneficial ownership of lululemon athletica inc. common stock, which remains at 8.4% (9,901,004 shares) for Wilson. On March 5, 2026, Wilson launched the CreativityFirstlulu.com website via press release, advocating steps to restore investor confidence such as empowering creative leadership and nominating three independent director candidates—Marc Maurer, Laura Gentile, and Eric Hirshberg—for election at the Annual Meeting.

• ·Reporting Persons include Dennis J. Wilson, Anamered Investments Inc., LIPO Investments (USA), Inc., Wilson 5 Foundation, Wilson 5 Foundation Management Ltd., Five Boys Investments ULC, Shannon Wilson, Low Tide Properties Ltd., House of Wilson Ltd., Laura Gentile, Eric Hirshberg, and Marc Maurer.
• ·No change in shares since Amendment No. 13 filed February 27, 2026.

09-03-2026

Shenandoah Telecommunications Company (SHEN) filed Definitive Additional Materials (DEFA14A) on March 09, 2026, as a proxy statement pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as soliciting material under Rule 14a-12.

• ·Filing Type: DEFA14A (Definitive Additional Materials)
• ·Filed by the Registrant

09-03-2026

Nano Nuclear Energy Inc. (NNE) filed an amended S-3 shelf registration statement (No. 333-288982) with the SEC on March 9, 2026, enabling the potential offer and sale of various securities for total gross proceeds of up to $900M over time via prospectus supplements. The filing highlights the company's focus on developing advanced nuclear reactors and related services but emphasizes its pre-revenue status, with no current financial performance data provided. Extensive risk factors are disclosed, including challenges in design, regulatory approval, funding, and supply chain for nuclear technologies.

• ·Registration No. 333-288982
• ·Prospectus date: [●], 2026

09-03-2026

Lyell Immunopharma, Inc. appointed Smital Shah as Chief Financial and Business Officer and principal financial officer effective March 9, 2026, succeeding Lynn Seely, M.D., who had served as interim principal financial officer. Ms. Shah brings extensive experience from roles at ProQR Therapeutics, Gilead Sciences, and others in biotech finance and business development. Compensation includes a $500,000 base salary, target bonus up to 50% of base, and stock options for 140,000 shares vesting 25% after one year and monthly thereafter.

• ·Event approved by Board on March 6, 2026; offer letter dated March 3, 2026.
• ·Ms. Shah provided finance and business development consulting to Lyell since February 2026.
• ·Stock option under 2021 Equity Incentive Plan; exercise price equals fair market value on grant date.
• ·Ms. Shah participates in Officer Severance Plan as Tier I Employee.
• ·Standard indemnification agreement entered with Ms. Shah.

09-03-2026

Fidelity National Information Services, Inc. (FIS) entered into underwriting agreements on March 4, 2026, for $6.8B in USD Senior Notes (including $2B 4.450% due 2028, $2.3B 4.550% due 2029, $500M Floating Rate due 2029, and $2B 4.800% due 2031) and on March 5, 2026, for €1B in Euro Senior Notes (€500M Floating Rate due 2028 and €500M 3.450% due 2030), with closings expected on March 10, 2026. The offerings are pursuant to an S-3 registration statement. No period-over-period financial comparisons are provided in the filing.

• ·Underwriting agreements filed as Exhibits 1.1 (USD, dated March 4, 2026) and 1.2 (Euro, dated March 5, 2026).
• ·Offerings reference S-3 Registration Statement (File No. 333-288198), filed June 20, 2025, amended February 26, 2026.
• ·Prospectus supplements and free writing prospectuses filed February 26, March 4-6, 2026.

09-03-2026

Circle Internet Group, Inc. (CRCL) reported robust growth in its core stablecoin business, with USDC in circulation surging 72% YoY to $75.3B at December 31, 2025 (from $43.9B), driving total revenue and reserve income up 63.9% YoY to $2.75B. However, the company posted a net loss of $70M in 2025 versus a $157M profit in 2024, due to operating expenses ballooning 139.9% YoY to $1.18B (led by compensation expenses +220.7%), resulting in an operating loss and RLDC margin remaining flat at 39%. Adjusted EBITDA rose strongly to $582M (54% margin) from $285M (43% margin), highlighting non-GAAP operational strength amid GAAP challenges.

• ·Net cash provided by operating activities increased to $542M in 2025 from $345M in 2024.
• ·Net cash provided by financing activities rose to $31.9B in 2025 from $19.5B in 2024, driven by equity raises reflected in stockholders' equity growth to $3.3B.
• ·Redeemable convertible preferred stock redeemed in full ($1.1B liquidation preference).
• ·Cash and cash equivalents segregated for stablecoin holders grew 70.9% to $75.1B.

09-03-2026

Deluxe Corporation (DLX) issued a DEFA14A notice for its 2026 Annual Meeting of Shareholders, to be held virtually on April 23, 2026 at 3:00 PM CDT. Key proposals include the election of nine director nominees, an advisory (non-binding) vote to approve Named Executive Officer compensation, approval of Amendment No. 3 to the 2022 Stock Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026. Voting must be completed by April 22, 2026, 11:59 PM ET.

• ·Proxy materials available online at www.ProxyVote.com; paper/email requests due by April 9, 2026
• ·Virtual meeting access: www.virtualshareholdermeeting.com/DLX2026
• ·Board recommends 'For' on all proposals